David Oberlin, MD

David Oberlin, MD, is a board-certified dermatologist practicing in Grand Rapids and Hastings, Michigan.

Articles by David Oberlin, MD

Q&A: Why APEX May Not Prove Guselkumab is Superior for PsA Joints

September 15th 2026

Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for a patient with psoriatic arthritis.

Q&A: How Trial Enrichment Shaped APEX's Radiographic Findings in Psoriatic Disease

ByDavid Oberlin, MD

September 14th 2026

David Oberlin, MD, explains why APEX's enriched trial population, not drug mechanism, likely drove its unique radiographic success in psoriatic arthritis.

What Baseline Disease Severity Hides in PsA Trial Data, With David Oberlin, MD

ByDavid Oberlin, MD

September 9th 2026

David Oberlin, MD, on why trial enrichment, not mechanistic superiority, likely explains differing radiographic results in PsA drug trials.

Latest Updated Articles

What Baseline Disease Severity Hides in PsA Trial Data, With David Oberlin, MD
September 9th 2026
Q&A: Why APEX May Not Prove Guselkumab is Superior for PsA Joints
September 15th 2026

David Oberlin, MD

Articles by David Oberlin, MD

Q&A: Why APEX May Not Prove Guselkumab is Superior for PsA Joints

Q&A: How Trial Enrichment Shaped APEX's Radiographic Findings in Psoriatic Disease

What Baseline Disease Severity Hides in PsA Trial Data, With David Oberlin, MD

Latest Updated Articles

Trending on HCPLive

Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD

Advances in Treating High-Impact Psoriasis from EADV 2026

From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class

FDA Updates Sotatercept Label, ERS Releases PAH Guidelines to Include HYPERION Data

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels